Home
Clinical Trials
Avelumab and Talazoparib in U...

Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)

Last Updated: 2023-04-06

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Total Enrollment

79 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-07-19

Study Completion Date

2021-12-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

JAVELIN Ovarian PARP 100 (B9991030) is an open-label, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV). On March 19, 2019, Sponsors alliance announced the discontinuation of the ongoing Phase III study, and the decision was based on several factors, including previous announced interim results from JAVELIN Ovarian 100 study (B9991010). Patients who remain in B9991030 study will continue receiving their randomized treatment assigned and will be monitored for appropriate safety assessments until treatment discontinuation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

NCT02718417

Ovarian Cancer

TERMINATED PHASE3

Paclitaxel + Carboplatin With AVB-S6-500 in Women With Stage III or IV Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Receiving Neoadjuvant Chemotherapy

NCT03607955

Epithelial Ovarian Cancer Primary Peritoneal Carcinoma Fallopian Tube Cancer

WITHDRAWN PHASE1

Pilot Study of Taxol, Carboplatin, and Bevacizumab in Advanced Stage Ovarian Carcinoma Patients

NCT00127920

Ovarian Neoplasms

COMPLETED PHASE2

ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

NCT05071937

Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer

RECRUITING PHASE2

Carboplatin Taxol Avastin in Ovarian Cancer (OVCA)

NCT00129727

Ovarian Cancer

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

JAVELIN Ovarian PARP 100 (B9991030) is an open-label, international, multi-center, randomized study designed to evaluate the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV). The primary endpoint is progression-free survival (PFS) as determined based on blinded independent central review (BICR) assessment per RECIST v1.1.

On March 19, 2019, Sponsors alliance announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study. The alliance has notified health authorities and trial investigators of the decision to discontinue the trial. The decision was based on several emerging factors since the trial's initiation, including the previously announced interim results from JAVELIN Ovarian 100 study (B9991010), which was stopped due to futility of efficacy at a planned interim analysis on 21 December 2018. The alliance determined that the degree of benefit observed with avelumab in frontline ovarian cancer in that study does not support continuation of the JAVELIN Ovarian PARP 100 trial in an unselected patient population and emphasizes the need to better understand the role of immunotherapy in ovarian cancer. Additional factors include the rapidly changing treatment landscape and the approval of a PARP inhibitor in the frontline maintenance setting. The decision to discontinue the JAVELIN Ovarian PARP 100 trial was not made for safety reasons.

Patients who remain in the study will continue receiving investigational products according to their randomized treatment assignment and will be monitored for appropriate safety assessments until treatment discontinuation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ovarian Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

chemotherapy, avelumab and talazoparib

Platinum-based chemotherapy + avelumab followed by avelumab + talazoparib maintenance

Group Type EXPERIMENTAL

Chemotherapy + avelumab followed by avelumab + talazoparib

Intervention Type DRUG

Chemotherapy Period Paclitaxel Carboplatin Avelumab

Maintenance Period Avelumab Talazoparib

chemotherapy, and talazoparib

Platinum-based chemotherapy followed by talazoparib maintenance

Group Type EXPERIMENTAL

Chemotherapy followed by talazoparib maintenance

Intervention Type DRUG

Chemotherapy Period Paclitaxel Carboplatin

Maintenance Period Talazoparib

chemotherapy and bevacizumab

Platinum-based chemotherapy + bevacizumab followed by bevacizumab maintenance

Group Type ACTIVE_COMPARATOR

Chemotherapy + bevacizumab followed by bevacizumab

Intervention Type DRUG

Chemotherapy Period Paclitaxel Carboplatin Bevacizumab

Maintenance Period Bevacizumab

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chemotherapy + avelumab followed by avelumab + talazoparib

Chemotherapy Period Paclitaxel Carboplatin Avelumab

Maintenance Period Avelumab Talazoparib

Intervention Type DRUG

Chemotherapy followed by talazoparib maintenance

Chemotherapy Period Paclitaxel Carboplatin

Maintenance Period Talazoparib

Intervention Type DRUG

Chemotherapy + bevacizumab followed by bevacizumab

Chemotherapy Period Paclitaxel Carboplatin Bevacizumab

Maintenance Period Bevacizumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed Stage III IV epithelial ovarian, fallopian tube, or primary peritoneal cancer including carcinosarcoma with high-grade serous component.
* Patients must be candidates for bevacizumab in combination with platinum based chemotherapy and previously untreated.
* Must have completed a primary surgical debulking procedure, or be candidates for neoadjuvant chemotherapy with planned interval debulking surgery.

1. Patients who completed primary debulking must have had incompletely resected disease that is macroscopically/grossly visible and at least with lesions \>1 mm and be randomized at a maximum of 8 weeks after surgery.
2. For patients who are candidates for neoadjuvant chemotherapy, the diagnoses must have been confirmed by:

* Core tissue (not fine-needle aspiration) biopsy is required for diagnosis.
* Stage IIIC-IV documented via imaging or surgery (without attempt at cytoreduction).
* Serum CA-125/CEA ratio \>25. If the serum CA-125/CEA ratio is \<25, then workup should be negative for the presence of a primary gastrointestinal or breast malignancy (\<6 weeks before start of neoadjuvant treatment).
* Randomization must occur within 8 weeks after diagnosis.
* Availability of an archival FFPE tumor tissue block or a minimum of 25 slides, together with an accompanying original H\&E slide. If archived FFPE tissue is not available, a de novo (ie, fresh) tumor sample must be obtained in accordance with local institutional practice for tumor biopsies. Tumor tissue must contain 40% or greater tumor nuclei per central laboratory assessment.
* ECOG performance status 0-1
* Age \>=18 years (or \>=20 years in Japan).
* Adequate bone marrow, hepatic, and renal function and blood coagulation

Exclusion Criteria

* Non-epithelial tumors or ovarian tumors with low malignant potential (ie, borderline tumors) or mucinous tumors.
* Patients for whom intraperitoneal cytotoxic chemotherapy is planned.
* Prior exposure to immunotherapy with interleukin (IL)-2, interferon alpha (IFN-α), or an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-cytotoxic T-lymphocyte associated antigen 4 (anti-CTLA4) antibody (including ipilimumab), or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways, excluding therapeutic anticancer vaccines.
* Prior treatment with a PARP inhibitor.
* Prior treatment with any anti-vascular endothelial growth factor (VEGF) drug, including bevacizumab.
* Major surgery (other than debulking or exploratory surgery for ovarian cancer) for any reason within 4 weeks prior to randomization and/or incomplete recovery from surgery.
* Prior radiotherapy to any portion of the abdominal cavity or pelvis. Prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease.
* Prior targeted therapy (including but not limited to vaccines, antibodies, tyrosine kinase inhibitors) or hormonal therapy for management of their ovarian, peritoneal primary or fallopian tube carcinoma.
* Prior organ transplantation including allogenic stem cell transplantation.
* Diagnosis of Myelodysplastic Syndrome (MDS).
* Known symptomatic brain metastases requiring steroids. Patients with previously diagnosed brain metastases are eligible if they have completed their treatment and have recovered from the acute effects of radiation therapy or surgery prior to study enrollment, have discontinued corticosteroid treatment for these metastases for at least 4 weeks and are neurologically stable.

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Arizona Oncology Associates, PC - HAL

Phoenix, Arizona, United States

Site Status

Arizona Oncology Associates, PC - HAL

Phoenix, Arizona, United States

Site Status

Arizona Oncology Associates, PC - HAL

Scottsdale, Arizona, United States

Site Status

Arizona Oncology Associates, PC - HAL

Tempe, Arizona, United States

Site Status

Arizona Oncology Associates, PC - HOPE

Tucson, Arizona, United States

Site Status

Arizona Oncology Associates, PC - HOPE

Tucson, Arizona, United States

Site Status

Sansum Clinic

Santa Barbara, California, United States

Site Status

Sansum Clinic

Solvang, California, United States

Site Status

Smilow Cancer Hospital at Yale-New Haven

New Haven, Connecticut, United States

Site Status

NYU Winthrop Hospital, Gynecologic Oncology

Mineola, New York, United States

Site Status

NYU Winthrop Hospital, Infusion Center

Mineola, New York, United States

Site Status

NYU Winthrop Radiology

Mineola, New York, United States

Site Status

Montefiore Medical Center - EPC

The Bronx, New York, United States

Site Status

Montefiore Medical Center, Department of Obstetrics and Gynecology and Women's Health

The Bronx, New York, United States

Site Status

Montefiore Medical Center

The Bronx, New York, United States

Site Status

Montefiore Medical Center-Centennial Facility

The Bronx, New York, United States

Site Status

Oncology Hematology Care, Inc.

Cincinnati, Ohio, United States

Site Status

Oncology Hematology Care Inc

Cincinnati, Ohio, United States

Site Status

Oncology Hematology Care Inc

Cincinnati, Ohio, United States

Site Status

Oncology Hematology Care, Inc.

Cincinnati, Ohio, United States

Site Status

Northwest Cancer Specialists, P.C.

Portland, Oregon, United States

Site Status

Northwest Cancer Specialists, P.C.

Portland, Oregon, United States

Site Status

Northwest Cancer Specialists, P.C.

Portland, Oregon, United States

Site Status

Northwest Cancer Specialists, P.C.

Tualatin, Oregon, United States

Site Status

Tennessee Oncology, PLLC

Dickson, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Franklin, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Gallatin, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Hermitage, Tennessee, United States

Site Status

Tennessee Oncology, PLLC

Lebanon, Tennessee, United States

Site Status